| 1 |
Feldmann H, Geisbert TW.Ebola haemorrhagic fever[J]. Lancet, 2011, 377(9768): 849-862.
|
| 2 |
Meyers L, Frawley T, Goss S, et al.Ebola virus outbreak 2014: clinical review for emergency physicians[J]. Ann Emerg Med, 2015, 65(1): 101-108.
|
| 3 |
Bray M. Pathogenesis of viral hemorrhagic fever[J]. Cur Opini Immunol, 2005, 17(4): 399-403.
|
| 4 |
Green A. Ebola emergency meeting establishes new control centre[J]. Lancet , 2014, 384(9938): 118.
|
| 5 |
WHO Ebola Response Team.Ebola Virus Disease among Male and Female Persons in West Africa[J]. N Engl J Med, 2016, 374(1): 96-98.
|
| 6 |
Bausch DG, Towner JS, Dowell SF, et al.Assessment of the risk of Ebola virus transmission from bodily fluids and fomites[J]. J Infect Dis, 2007, 196 Suppl 2: S142-147.
|
| 7 |
Thorson A, Formenty P, Lofthouse C, et al.Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations[J]. BMJ open, 2016, 6(1): e008859.
|
| 8 |
Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers[J]. Lancet Infect Dis, 2004, 4(8): 487-498.
|
| 9 |
Ramanan P, Shabman RS, Brown CS, et al.Filoviral immune evasion mechanisms[J]. Viruses, 2011, 3(9): 1634-1649.
|
| 10 |
Beeching NJ, Fenech M, Houlihan CF, et al.Ebola virus disease[J]. BMJ, 2014, 349: g7348.
|
| 11 |
Markosyan RM, Miao C, Zheng YM, et al.Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger[J]. PLoS Pathogens, 2016, 12(1): e1005373.
|
| 12 |
Kumar A. Ebola virus altered innate and adaptive immune response signalling pathways: Implications for novel therapeutic approaches[J]. Infect Disord Drug Targets, 2016, 16(2): 79-94.
|
| 13 |
Baize S, Leroy EM, Georges-Courbot MC, et al.Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients[J]. Nat Med, 1999, 5(4): 423-426.
|
| 14 |
Bradfute SB, Warfield KL, Bavari S, et al.Functional CD8＋ T cell responses in lethal Ebola virus infection[J]. J Immunol, 2008, 180(6): 4058-4066.
|
| 15 |
Fletcher TE, Fowler RA, Beeching NJ, et al.Understanding organ dysfunction in Ebola virus disease[J]. Intensive Care Med, 2014, 40(12): 1936-1939.
|
| 16 |
Brizendine KD.Ebola virus: questions, answers, and more questions[J]. Cleve Clin J Med, 2014, 81(12): 729-735.
|
| 17 |
Peters CJ, Jahrling PB, Khan AS.Patients infected with high-hazard viruses: scientific basis for infection control[J]. Arch Virol Suppl, 1996, 11: 141-168.
|
| 18 |
Gao X, Rong G, Lu Y, et al.Symptoms closely associated with Ebola virus disease[J]. Lancet Infect Dis, 2016, 16(1): 18-19.
|
| 19 |
Mendoza EJ, Qiu X, Kobinger GP.Progression of Ebola Therapeutics During the 2014-2015 Outbreak[J]. Trends Mol Med, 2016, 22(2): 164-73.
|
| 20 |
Li J, Duan HJ, Chen HY, et al.Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients[J]. Int J Infect Dis, 2016, 42: 34-39.
|
| 21 |
Cournac JM, Karkowski L, Bordes J, et al.Rhabdomyolysis in Ebola Virus Disease.Results of an Observational Study in a Treatment Center in Guinea[J]. Clin Infect Dis, 2016, 62(1): 19-23.
|
| 22 |
Dedkov VG, Magassouba NF, Safonova MV, et al.Development and evaluation of a real-time RT-PCR assay for the detection of Ebola virus (Zaire) during an Ebola outbreak in Guinea in 2014-2015[J]. J Virol Methods, 2016, 228: 26-30.
|
| 23 |
Martin P, Laupland KB, Frost EH, et al.Laboratory diagnosis of Ebola virus disease[J]. Intensive Care Med, 2015, 41(5): 895-898.
|
| 24 |
Baştu ğ A, Bodur H. Ebola viral disease: What should be done to combat the epidemic in 2014? [J]. Turk J Med Sci, 2015, 45(1): 1-5.
|
| 25 |
Gignoux E, Azman AS, de Smet M, et al.Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease[J]. N Engl J Med, 2016, 374(1): 23-32.
|
| 26 |
Enserink M. Infectious diseases.Ebola drugs still stuck in lab[J]. Science, 2014, 345(6195): 364-365.
|
| 27 |
van Griensven J, Edwards T, de Lamballerie X, et al.Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea[J]. N Engl J Med, 2016, 374(1): 33-42.
|
| 28 |
van Griensven J, De Weiggheleire A, Delamou A, et al.The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field[J]. Clin Infect Dis, 2016, 62(1): 69-74.
|
| 29 |
Qiu X, Wong G, Audet J, et al.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp[J]. Nature, 2014, 514(7520): 47-53.
|
| 30 |
向德栋，支轶，杨智清，等.5例埃博拉病毒患者的临床特征分析[J]．第三军医大学学报，2015，37(4)：4.
|
| 31 |
Wang Y, Cui R, Li G, et al.Teicoplanin inhibits Ebola pseudovirus infection in cell culture[J]. Antiviral Res, 2016, 125: 1-7.
|
| 32 |
Tapia MD, Sow SO, Lyke KE, et al.Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial[J]. Lancet Infect Dis, 2016, 16(1): 31-42.
|
| 33 |
Vandebosch A, Mogg R, Goeyvaerts N, et al.Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges[J]. Clin Trials, 2016, 13(1): 57-65.
|
| 34 |
Reina J. [Current status of drug treatment against the disease caused by the Ebola virus] [J]. Rev Esp Quimioter, 2016, 29(1): 1-7.
|
| 35 |
Kucharski AJ, Eggo RM, Watson CH, et al.Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease[J]. Emerg Infect Dis, 2016, 22(1): 105-108.
|